Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease (SUMMIT AD)

This study has been completed.

Sponsor:

Collaborator:

Pfizer

Information provided by (Responsible Party):

JANSSEN Alzheimer Immunotherapy Research & Development, LLC

ClinicalTrials.gov Identifier:

NCT01254773

First received: December 3, 2010

Last updated: February 13, 2013

Last verified: February 2013

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been completed.
Study Completion Date:	January 2013
Primary Completion Date:	January 2013 (Final data collection date for primary outcome measure)